900174-92-7

Upstream product

• 900174-91-6 C₇H₉FN₂ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1427-07-2 2-fluoro-4-nitrotoluene 
• 127349-56-8 1-(bromomethyl)-2-fluoro-4-nitrobenzene 
• 1402586-10-0 2-(2-fluoro-4-nitrobenzyl)isoindoline-1,3-dione 
• 1402586-54-2 C₁₂H₁₅FN₂O₄ 

Downstream Products

• 1402586-18-8 C₁₉H₂₁FN₂O₄ 
• 1402586-19-9 C₂₇H₃₃ClFN₅O₃ 
• 1402581-76-3 1-[4-(aminomethyl)-3-fluorophenyl]-3-[[5-tert-butyl-2-(3-chlorophenyl)-2H-pyrazol-3-yl]methyl]urea 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN N-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (R) bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS

The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.